- Atossa Genetics (ATOS) voluntarily recalls the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test to "address concerns raised by the FDA."
- The issues the regulator raised include: "Concerns about the current instructions for use, certain promotional claims used to market the devices, and the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid specimen collection process." (PR)
- Shares are halted.
From other sites
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Dec 30, 2014)
at MarketWatch.com (Sep 24, 2014)
at MarketWatch.com (Sep 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs